Tagged with Clinical Trials

CRO The general manager of one of the leading CROs in Romania explains how the country in gathering pace as a top tier clinical trials destination country within the region and how the priority is now about on-time project delivery. Could you please start by introducing PSI and its engagement with…

Janssen The country manager of one of the foremost providers of sustainable and integrated healthcare solutions describes the sorts of local adaptations that need to be enacted when launching a product on the Romanian market. He also speaks extensively about the state of the local medical device market and its likely future potential. Can…

Actelion Turkey has been a high priority market for Actelion since the company’s relatively recent beginnings, and the general manager of the local affiliate discusses his affiliate efforts to improve awareness around this rare disease through open communication with health authorities, and the need for formal recognition of orphan drugs by…

Bayer Bayer Turkey’s healthcare division head discusses how the company adapted to the post 2009 pharmaceutical pricing environment by shrinking their portfolio and focusing strongly on key growth products, launched recently from its R&D pipeline. The affiliate is also focusing on its role as a contributor to Turkish society with R&D,…

hospitals Medipol hospital’s medical director discusses the private institution’s current role in the Turkish healthcare system, and their plans for expansion in the coming years.  How did Medipol come into existence, and where does the hospital stand today? Medipol was opened three years ago, and today the hospital has 500 beds,…

clinical trials The growth of clinical trials in Korea has been remarkable in recent years. The number of clinical trials performed by multinationals has shot up from five in 2000 to 303 in 2012, with 367 clinical trials performed by local companies. In the same year, Seoul was ranked the number one…

R&D Pfizer Turkey has taken a strong supporting role in Turkey’s current strategic development plan by localizing the production of their Prix Galien winning Prevnar vaccine. Country Manager Elif Aral discusses this facility’s role as a role model in the industry, and how the country can improve investment incentives to better…

AstraZeneca Rodrigo Fernandez became country president of AstraZeneca Central America, Caribbean, and Middle Andean Countries (CAMCARMAC) in July 2013. He discusses the challenges across the region for regulation and distribution channels, with an emphasis on the complexities of the Peruvian market. What were your initial priorities when you became head of…

Celgene Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the market, how pro-patients and pro-innovation policies need to be supported, how innovative ways need to be found to ensure patient…

clinical trials The president of the association representing clinical research organisations speaks out about Romania’s attractiveness as a destination country in an era of clinical research globalisation. He further sheds ideas on fostering greater in-country R&D activity and outlines his personal vision for developing the association. How did the association come into…

Ipsen Mexico is a key market for Ipsen to consolidate its footprint in the Americas. The recently appointed general manager and the medical director of the Mexican affiliate discuss how penetrating the market is a hard, yet not impossible mission, how Mexican patients are increasingly involved in Ipsen’s global clinical trials…

Novartis Novartis strives for “creating solutions for patients that go beyond the pill”. The country head and next president of CANIFARMA discusses how the company is using new programs and technology to get innovation to patients, how the recent work of COFEPRIS is helping get drugs to patients faster and why…